Cassava Sciences, Inc. (NASDAQ:SAVA - Get Free Report)'s stock price traded down 6.3% on Tuesday . The company traded as low as $20.13 and last traded at $20.16. 341,502 shares were traded during trading, a decline of 56% from the average session volume of 776,676 shares. The stock had previously closed at $21.52.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a "buy" rating and issued a $124.00 price objective on shares of Cassava Sciences in a report on Tuesday, March 5th.
Read Our Latest Analysis on SAVA
Cassava Sciences Stock Performance
The stock's fifty day moving average is $21.36 and its two-hundred day moving average is $20.61. The firm has a market cap of $944.15 million, a price-to-earnings ratio of -8.69 and a beta of -0.38.
Cassava Sciences (NASDAQ:SAVA - Get Free Report) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.10). Sell-side analysts predict that Cassava Sciences, Inc. will post -2.01 earnings per share for the current year.
Institutional Trading of Cassava Sciences
Large investors have recently modified their holdings of the company. Montag A & Associates Inc. grew its position in Cassava Sciences by 50.0% in the 3rd quarter. Montag A & Associates Inc. now owns 1,500 shares of the company's stock valued at $25,000 after buying an additional 500 shares in the last quarter. Northwest Financial Advisors bought a new position in Cassava Sciences in the 4th quarter valued at about $25,000. Benjamin F. Edwards & Company Inc. grew its position in Cassava Sciences by 653.6% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,153 shares of the company's stock valued at $26,000 after buying an additional 1,000 shares in the last quarter. Headlands Technologies LLC grew its position in Cassava Sciences by 24,044.4% in the 3rd quarter. Headlands Technologies LLC now owns 2,173 shares of the company's stock valued at $36,000 after buying an additional 2,164 shares in the last quarter. Finally, NBC Securities Inc. bought a new position in Cassava Sciences in the 3rd quarter valued at about $66,000. Institutional investors and hedge funds own 38.05% of the company's stock.
About Cassava Sciences
(
Get Free Report)
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cassava Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cassava Sciences wasn't on the list.
While Cassava Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
